|
Mar 19
|
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
|
|
Dec 21
|
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
|
|
Oct 25
|
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
|